Keith Basler
Otolaryngology · Brandon, FLNPI 1447592845
Payments from drug & device makers
Across 294 payments — averaging $36.20 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Intersect ENT, Inc.$2K
- GSK$1K
- Neurent Medical Limited$1K
- Regeneron Healthcare Solutions, Inc.$936
- AstraZeneca$784
- Optinose US, Inc.$571
- plus $3K from 27 others
What the payments were for
- Travel & lodging$1,71516%
- Food & beverage$8,75582%
- Education$1722%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Intersect ENT, Inc. | 8 | $2,423 |
| GSK | 61 | $1,429 |
| Neurent Medical Limited | 8 | $1,252 |
| Regeneron Healthcare Solutions, Inc. | 31 | $936 |
| AstraZeneca | 42 | $784 |
| Optinose US, Inc. | 24 | $571 |
| Sanofi | 20 | $481 |
| Biohaven Pharmaceuticals, Inc. | 7 | $309 |
| Johnson & Johnson | 2 | $293 |
| Acclarent, Inc | 13 | $276 |
| Medtronic(2 entities) | 3 | $246 |
| Kaleo, Inc. | 14 | $231 |
| Alk-abello, Inc | 16 | $226 |
| Aerin Medical Inc. | 8 | $219 |
| Integra Lifesciences Corporation | 6 | $150 |
| Cook Medical LLC | 1 | $119 |
| Hikma Pharmaceuticals USA | 5 | $86 |
| Biohaven Pharmaceutical Holding Company Ltd. | 4 | $78 |
| Sanofi-aventis U.S. LLC | 1 | $75 |
| Pfizer | 4 | $66 |
| Itamar Medical Inc | 1 | $61 |
| C2dx, Inc | 1 | $46 |
| Organogenesis Inc. | 1 | $38 |
| Merz Pharmaceuticals, LLC | 2 | $38 |
| Boehringer Ingelheim | 2 | $31 |
| Stryker | 1 | $30 |
| Phadia US Inc. | 2 | $29 |
| CTL Medical Corporation | 1 | $25 |
| Smith+Nephew | 1 | $24 |
| Genentech USA, Inc. | 1 | $20 |
| Amgen | 1 | $20 |
| Checkpoint Surgical, Inc | 1 | $16 |
| Kowa Pharmaceuticals America, Inc. | 1 | $14 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- SINUVA$2,279
- NEUROMARK Radiofrequency Console$1,147
- NEUROMARK Device$1,003
- NURTEC ODT$249
- MATRIXMANDIBLE$147
- PROPEL$146
- NA$146
- NEUROMARK System$143
- Xhance$140
- Zenith Spiral-Z$119
- VIVAER STYLUS$118
- RHINAER STYLUS$118
- DUPIXENT$117
- NUCALA$113
How this compares
$10,643 in reported general payments places this provider in the 85th percentile of 586 otolaryngology providers in Florida.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Breo ElliptaFluticasone/Vilanterol | 18 | $7,607 |
| Fluticasone Propionate | 348 | $5,201 |
| Ipratropium Bromide | 92 | $2,914 |
| Fluocinolone Acetonide Oil | 72 | $2,815 |
| Epinephrine | 15 | $2,692 |
| Azelastine Hcl | 93 | $1,959 |
| Ofloxacin | 49 | $1,307 |
| Montelukast Sodium | 29 | $538 |
| Doxycycline Monohydrate | 30 | $528 |
| Mupirocin | 72 | $428 |
| Amoxicillin-Clavulanate PotassAmoxicillin/Potassium Clav | 40 | $405 |
| Prednisolone Acetate | 11 | $321 |
| Famotidine | 23 | $228 |
| Pantoprazole Sodium | 29 | $199 |
| Methylprednisolone | 31 | $153 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| GSKBreo Ellipta | $1,429 | $7,60718 claims |
| Hikma Pharmaceuticals USAEpinephrine | $86 | $2,69215 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 85th percentile of 586 otolaryngology providers in Florida.
Other otolaryngology in Brandon
- Scott PowellBrandon$72K
- Craig ShapiroHollywood$8.1M
- Adrien EshraghiMiami$2.1M
- Cecelia DamaskOrlando$771K
- Ralph TufanoSarasota$733K
- Mitchell MillerClearwater$709K
- Brian KerrGainesville$629K
- Maria SuurnaMiami$456K
- Mark TaborTampa$348K
- Franklin RimellFort Myers$314K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.